Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema

Phase 4

Terminated

• Conditions: Diabetes Mellitus, Type II
• Interventions: Drug: Empagliflozin; Drug: Glimepiride; Drug: Glimepiride placebo; Drug: Empagliflozin placebo

• Registration Number: NCT02985242
• Lead Sponsor: Hannover Medical School

Brief Summary

This is a prospective, randomized, active control, two-arm parallel, double-blind, monocenter phase IV clinical trial. The trial compares empagliflozin to glimepiride in patients with type 2 diabetes mellitus in addition to standard of care treatment.

Patients with type 2 diabetes mellitus who are between 18 and 80 years of age will be recruited for the clinical trial and randomly allocated to either receive empagliflozin or glimepiride.

The assumption of the study is that empagliflozin slows down diabetic retinopathy progression rate and thus a lower microaneurysm formation rate compared to subjects treated with glimepiride by substantially decreased cellular glucotoxicity will be achieved.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-11-25
• Study First Submitted QC: 2016-12-02
• Study First Posted: 2016-12-07
• Study Start: 2017-06-12
• Primary Completion: 2018-08-01
• Study Completion: 2018-08-16
• Status Verified: 2018-09
• Last Update Submitted: 2018-09-26
• Last Update Posted: 2018-09-27

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

1. women and men between 18 - 80 years of age

2. type 2 diabetes mellitus

3. early to moderate stage diabetic retinopathy (ETDRS: 20 (microaneurysms only) to 35 (microaneurysms/ hemorrhages and/or hard exsudates)) in one or both eyes

4. stable HbA1c (± 0.5%) for at least 12 weeks

5. antidiabetic treatment with either diet, metformin, DPP4, GLP1, pioglitazone, acarbose, or respective combinations

6. HbA1c ≥ 6.5 and ≤ 10.0 %

7. body mass index < 46 kg/m2

8. office blood pressure ≤ 150/95 mmHg (confirmed on a second day; 24h ambulatory blood pressure measurement (ABPM) is allowed to check accuracy of office values; inclusion with 24h mean blood pressure ≤ 145/90 mm Hg is possible); patients with hypertension should be treated according to current treatment guidelines

9. either women without childbearing potential defined by:

   • at least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral oophorectomy
   • hysterectomy
   • ≥ 50 years and in postmenopausal state > 1 year
   • < 50 years and in postmenopausal state > 1 year with serum follicle stimulating hormone (FSH) > 40 IU/l and serum estrogen < 30 ng/l or a negative estrogen test, both at screening or women of childbearing potential with a negative serum beta human chorionic gonadotropin (ß-hCG) pregnancy test at screening who agree to meet one of the following criteria from the time of screening, during the study and for a period of 4 days following the last administration of study medication:
   • correct use of one of the following accepted contraception methods: hormonal contraceptives (combined oral contraceptives, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release), intrauterine device (IUD/IUS) or a double barrier method, e.g. condom and occlusive cap (diaphragm or cervical/vault caps) with spermicide (foam, gel, film, cream or suppository)
   • true abstinence (periodic abstinence and withdrawal are not acceptable methods of contraception)
   • sexual relationship only with female partners
   • sterile male partners

10. signed written informed consent and willingness to comply with treatment and follow-up procedures

11. capability of understanding the investigational nature, potential risks and benefits of the clinical trial

Exclusion Criteria

1. Type 1 diabetes
2. uncontrolled diabetes mellitus type 2 with fasting glucose > 13.3 mmol/l confirmed on a second day
3. known or suspected hypersensitivity to empagliflozin, glimepiride, or any excipients; and / or known or suspected hypersensitivity to sulfonylureas, sulfonamides or SGLT2 inhibitors in general
4. history of multiple severe hypoglycemic episodes within the last two years
5. use of Insulin, SGLT2-inhibitor, sulfonylurea derivate or a glinide within past 3 months
6. clinical significant macular edema in both eyes and indication for intravitreal anti-VEGF treatment for both eyes at screening or baseline visit. Eyes with a small amount of intraretinal or subretinal fluid (seen in OCT) but no need for intravitreal treatment as judged by the investigator (according to current practice patterns) may be included. Eyes with a history of intravitreal treatment of macular edema which do not need ongoing intravitreal treatment at the time of screening may be included.
7. eye diseases or pathologies that prevent clear ophthalmoscopy and evaluation of study parameters, thus not allowing study participation according to the investigator´s judgment, such as (but not only) vitreous hemorrhage, mature cataract, macular pathologies other than diabetic maculopathy
8. history of ketoacidosis or metabolic acidosis
9. use of loop diuretics
10. history of > 1 urogenital infection/year
11. any history of stroke, transient ischemic attack (TIA), instable angina pectoris or myocardial infarction within last 3 months prior to baseline visit
12. congestive heart failure New York Heart Association (NYHA) III and IV
13. severe valvular or left ventricular outflow obstruction disease needing intervention;
14. atrial fibrillation/flutter with a mean ventricular response rate at rest >100 beats per minute
15. chronic lower urinary tract infections (but not simple asymptomatic bacteriuria)
16. eGFR < 60 ml/min/1,73 m2 (MDRD-formula, confirmed on a second day)
17. chronic diarrhea, any clinical signs of volume depletion or a hematocrit > 48 % (women) and > 53 % (men)
18. elevated risk for volume depletion, e.g. history of severe volume depletion that required medical therapy
19. chronic liver disease (including known active hepatitis) and/or screening alanine transaminase (ALT) or aspartate transaminase (AST) > 3 x upper limit of normal (ULN) (confirmed on a second day)
20. Subjects with known seropositivity to human immunodeficiency virus.
21. acute illness at screening or randomization according to judgement by the investigator or patient
22. drug or alcohol abuse
23. psychosomatic or psychiatric diseases requiring hospitalization during the last 12 months
24. clinical evidence of current malignancy with exception of basal cell or squamous cell carcinoma of the skin, and cervical intraepithelial neoplasia (5 years prior to randomization)
25. any medical or surgical intervention planned for the next 13 months after randomization not allowing study participation according to the investigator´s judgment
26. current participation in any other clinical trial or participation in another clinical trial within 30 days before screening

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Empagliflozin/glimepiride placebo	Glimepiride placebo	Empagliflozin 25 mg film-coated tablet p.o. daily and glimepiride matching placebo p.o. daily Duration of treatment: 12 months
Glimepiride/empagliflozin placebo	Empagliflozin placebo	Glimepiride 2 mg tablet p.o. daily and empagliflozin matching placebo p.o. daily Duration of treatment: 12 months
Empagliflozin/glimepiride placebo	Empagliflozin	Empagliflozin 25 mg film-coated tablet p.o. daily and glimepiride matching placebo p.o. daily Duration of treatment: 12 months
Glimepiride/empagliflozin placebo	Glimepiride	Glimepiride 2 mg tablet p.o. daily and empagliflozin matching placebo p.o. daily Duration of treatment: 12 months

Primary Outcome Measures

Name	Time	Method
Microaneurysm formation rate over 12 months, i.e. number of newly developed microaneurysms within 12 months	Weeks 27 and 52

Secondary Outcome Measures

Name	Time	Method
Change in microaneurysm count	Weeks 27 and 52
Microaneurysm formation rate after 6 months (compared to baseline)	after 6 months
Change in diabetic retinopathy stage (≥ 2 step change on ETDRS severity score)	Weeks 27 and 52
Change in retinal thickness (as measured by Optical Coherence Tomography)	Weeks 27 and 52
Change in retinal perfusion of microvasculature within the retina (flow in Optical Coherence Tomography Angiography)	Weeks 27 and 52
Progression to clinically significant macular edema (CSME)	Up to 52 weeks
Change in intraocular lipid content (hard exsudates)	Weeks 27 and 52
Change in composite clinical outcome evaluating progression to proliferative diabetic retinopathy (PDR) based on photography, angiography plus clinically important events defining PDR (e.g. vitreous haemorrhage)	Weeks 27 and 52
Change in best corrected visual acuity (BCVA [ETDRS letters])	Weeks 27 and 52
Change in HbA1c	Weeks 2, 7, 12, 17, 22, 27, 32, 37, 42, 47, 52 and 55
Change in fasting glucose	Weeks 2, 7, 12, 17, 22, 27, 32, 37, 42, 47, 52 and 55
Change in body weight and body fat mass	Weeks 27, 52 and 55
Change in ambulatory blood pressure	Weeks 27 and 52

Trial Locations

Locations (1)

Hannover Medical School, University Eye Hospital and CRC Core Facility Hannover; 🇩🇪 Hanover, Lower Saxony, Germany